Get the Stockscreener App
0.73
2.08%
0.0149
After Hours:
.73
AEON Biopharma Inc. stock is traded at $0.73, with a volume of 12,367.
It is up +2.08% in the last 24 hours and up +1.15% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$0.7151
Open:
$0.7
24h Volume:
12,367
Relative Volume:
0.15
Market Cap:
$19.20M
Revenue:
-
Net Income/Loss:
$-60.11M
P/E Ratio:
-0.1679
EPS:
-4.347
Net Cash Flow:
$-12.04M
1W Performance:
-1.30%
1M Performance:
+1.15%
6M Performance:
-41.13%
1Y Performance:
-12.85%
1-Day Range:
$0.70
$0.73
1-Week Range:
$0.70
$0.7501
52-Week Range:
$0.51
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.73 | 18.92M | 0 | -60.11M | -12.04M | -4.347 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
AEONAEON Biopharma Inc Latest SEC Filings - Finviz
Price to book forward of AEON Biopharma, Inc. – AMEX:AEON - TradingView
Enterprise value to revenue forward of AEON Biopharma, Inc. – AMEX:AEON - TradingView
AEON Biopharma, Inc. Class A Actuals & Estimates (AMEX:AEON) - TradingView
AEON Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Aeon Biopharma Inc For: 22 June By Investing.com - Investing.com Nigeria
[Form 4] AEON Biopharma, Inc. Insider Trading Activity - Stock Titan
AEON Biopharma (AEON) grants 222,684 RSUs to director Palmisano - Stock Titan
Director at AEON Biopharma (AEON) granted 222,684 RSUs - Stock Titan
AEON Biopharma (AEON) director awarded 222,684 RSUs in equity grant - Stock Titan
Director Carter granted 222,684 RSUs at AEON Biopharma (AEON) - Stock Titan
Aeon Biopharma Inc (AEON) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AEON BIOPHARMA INC (AEON) Stock Chart - ChartMill
AEON Biopharma shareholders approve directors and auditor slate - TipRanks
Aeon Biopharma Inc (AEON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aeon Biopharma Inc (AEON) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aeon Biopharma Inc (AEON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AEON Biopharma, Inc. Elects Each of Marc Forth and Seongsoo Park as Class III Directors of the Company's Board of Directors - marketscreener.com
AEON Biopharma (NYSE: AEON) investors back Class III board slate and KPMG - Stock Titan
Aeon Biopharma Inc (AEON) Institutional Confidence - TradingKey
Aeon Biopharma Inc (AEON) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aeon Biopharma Inc (AEON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aeon Biopharma Inc (AEON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aeon Biopharma Inc (AEON) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AEON Biopharma (AEON) Slides 7% as Selling Pressure Intensifies Near $0.67Wave Extension - newsline.com
AEON Biopharma (AEON) Holds Steady at $0.71 as Stock Consolidates Between Key Support and ResistanceSeasonality Effect - newsline.com
AEON Q4 2025 Earnings: Significant EPS Miss as Pre-Revenue Biotech Faces ChallengesRetail Earnings Report - newsline.com
Number of shareholders of AEON Biopharma, Inc. – AMEX:AEON - TradingView
AEON Biopharma Presents New Data Supporting Biosimilarity of ABP-450 to BOTOX at AHS 2026 Annual Meeting - Moomoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - The Manila Times
Botox biosimilar ABP-450 shows similar structure and activity - Stock Titan
AEON Biopharma Presents New Data Supporting Biosimilarity of ABP-450 to BOTOX® at AHS 2026 Annual Meeting - Quiver Quantitative
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (AEON) Surges 5.6% as Bulls Test Key Resistance at $0.80Factor ETF Flow - newsline.com
AEON Biopharma Edges Higher: Stock Rises 2.75% as it Tests Key ResistanceHigh Conviction Picks - The Legal Advocate
AEON Q4 2025 Earnings: Deep EPS Miss Amid Pre-Revenue StageEPS Miss Report - The Legal Advocate
AEON Biopharma Q4 2025 Earnings: Major EPS Miss and No Revenue Weigh on Investor SentimentEarnings Expansion Phase - Newser
AEON Biopharma Inc. (AEON) Q4 2025 Earnings: Significant EPS Miss and Stock Decline Amid Development ChallengesHigh Growth Earnings - Newser
AEON Biopharma Dips 2.74% as Stock Nears Critical Support at $0.76Watchlist Stock Ideas - Newser
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
AEON Stock Price, Quote & Chart | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON SEC FilingsAeon Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
AEON Biopharma shares fall over 2% on quarterly loss By Investing.com - Investing.com South Africa
AEON Biopharma shares fall over 2% on quarterly loss - Investing.com
AEON Biopharma Reports Q1 Financial Results - Intellectia AI
AEON Biopharma Releases Updated Investor Relations Presentation - TipRanks
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma (AEON) releases May 2026 corporate investor presentation via Form 8-K - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AEON Biopharma (NYSE: AEON) Q1 2026 loss, financing deals and going concern risk - Stock Titan
AEON Biopharma (NYSE: AEON) Q1 2026 loss, FDA boosts ABP-450 plan and debt cut - Stock Titan
AEON Biopharma Inc. Stock (AEON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Cap:
|
Volume (24h):